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A B S T R A C T
Objective: To examine changes in activity participation following abatacept treatment for
rheumatoid arthritis (RA), and which factors contributed to such changes.
Methods: Data were analyzed from the Abatacept in Inadequate responders to Methotrex-
ate (AIM) and Abatacept Trial in Treatment of Anti-TNF INadequate responders (ATTAIN)
clinical trials of abatacept in patients with RA. Activity participation was evaluated by the
validated Activity Participation Questionnaire (APaQ), along with measures of clinical re-
sponse and health-related quality of life. Changes in the APaQ during the two study periods
were compared between treatment groups. Multiple regression analyses were performed to
investigate the determinants of change in activity participation. The relationship between
clinical efficacymeasures (including lowdisease activity state [LDAS], DiseaseActivity Score
28-defined remission, and European League Against Rheumatism [EULAR] responses) and
changes in activity participation were investigated.
Results: Statistically significant, substantive improvements in activity participation were
observed over the entire study period in patients treated with abatacept. Abatacept-treated
patients showed improvements from baseline of 8.4 and 7.3 days in activity participation,
compared with 4.5 and 1.4 days in the placebo group (P 0.005 vs. placebo in both trials), at
the end of AIM and ATTAIN, respectively. The Short Form-36 physical and mental compo-
nent scores, patient global assessment, and the Health Assessment Questionnaire-Disabil-
ity Index score were found to be the strongest determinants of changes in activity partici-
pation. Patients who achieved LDAS, disease remission and good EULAR responses
experienced greater improvements in activity participation measures.
Conclusions: Abatacept treatment substantively and significantly improved patients’ abil-
ity to participate in their usual activities. The gain in activity was closely related to improve-
ments in clinical status, physical function and quality of life.
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The disabling course of rheumatoid arthritis (RA) severely im-
pairs a patient’s physical function, and often results in re-
duced participation in social activities, including work and
leisure [1,2]. This type of activity participation is central to a
patient’s health-related quality of life (HRQoL) and sense of
general well-being [3,4], and the inability to perform these ac-
tivities can have a profound impact on a patient’s psycholog-
ical and social health [4–6]. Capturing the patient’s perspec-
tive of how RA impacts their daily activities is not only critical
to improving patient care, but it can also help inform other
aspects of disease management, such as health policy and
resource allocation [7]. Improvement in a patient’s physical
functioning and subsequent return to normal activity is,
therefore, an important treatment goal for RA.
There is a large body of evidence demonstrating that ad-
vances in RA therapy have brought tremendous improve-
ments in terms of disease activity, physical function, and
HRQoL [8–13]. However, less is known about the extent to
which these clinical benefits impact patients’ daily lives, and
whether they translate into increased participation in daily
and social activities. Evaluation of the impact of therapy on
activity participation can provide valuable additional infor-
mation to supplement the information gained from standard
clinical and HRQoL assessments. This broader type of assess-
ment of RA treatment is of increasing interest to researchers
and in clinical practice [4,14], and is advocated by the concep-
tual model of the International Classification of Functioning,
Disability and Health (ICF) for RA. The current ICF model for
RA assessment consists of three components: functional im-
pairment, activity limitation, and activity participation [15–
17]. Although several measures are available to assess the im-
pact of treatment on functional impairment and activity
limitation, there has been a lack of direct measures that eval-
uate activity participation; as a result, this component has not
yet been sufficiently examined. To address this, the Activity
Participation Questionnaire (APaQ) was developed and vali-
dated [18]. The APaQ is a simple and directmeasure consisting
of two items that assess participation in usual daily activities,
which is applicable regardless of age, gender, andwork status,
as well as all cultural and socioeconomic groups. Usual daily
activities are defined as work, whether or not the work is
paid, and any other activities the patient participates in
during the day (e.g., household chores, personal care, etc.).
The term ‘activity participation’ used in the APaQ refers to
participation in usual daily activities.
The APaQ was developed under the guidance of practicing
rheumatologists, with expertise in outcomemeasures, to be a
simple and clinically relevant measure that could be easily
administered in a clinical trial setting [18]. The resulting two
items on the APaQ – activity limitation and activity participa-
tion – were derived from items on existing, validated ques-
tionnaires; the National Health Interview Survey Adult Core
Questionnaire and the 36-item Short Form-36 (SF-36), respec-
tively. During validation, both items of the questionnaire ex-
hibited strong correlation with clinical improvements (Amer-
ican College of Rheumatology [ACR] and European LeagueAgainst Rheumatism [EULAR] responses) and disease activity
(minimal disease activity), andmoderate correlationswith pa-
tient-reported outcomes (Health Assessment Questionnaire-
Disability Index [HAQ-DI], pain, fatigue and patient global as-
sessment), demonstrating construct validity. The APaQ also
indicated reliability, internal consistency, and sensitivity to
change [18].
Here we assess the effect of a biologic therapy, abatacept,
on patients’ participation in usual daily activities, and exam-
ine which factors contribute most to changes in activity par-
ticipation. Abatacept is a first-in-class, selective costimulation
modulator that inhibits full T-cell activation, and it has previ-
ously demonstrated clinical efficacy in patients with RA and
an inadequate response tomethotrexate (MTX) [19,20] or anti-
tumor necrosis factor (TNF) therapy [21]. Along with clinical
efficacymeasures and patient-reported outcomes, theAPaQ [18]
was assessed throughout the abatacept clinical trials, providing
an opportunity to evaluate the effect of abatacept treatment on
activity participation over time. Improvements in HRQoL with
abatacept have been reported previously [12,13]; the aim of the
current analysis is to determine whether abatacept treatment
also leads to gains in patient activity participation.
Methods
Study designs and patient populations
Data used in this analysis were obtained from two random-
ized double-blind, placebo-controlled, multicenter, multina-
tional, phase III clinical trials of abatacept in active RA pa-
tients: Abatacept in Inadequate responders to Methotrexate
(AIM) [19] and Abatacept Trial in Treatment of Anti-TNF INad-
equate responders (ATTAIN) [21]. The 12-month AIM study
included 652 patients randomized 2:1 to receive abatacept or
placebo on a background of MTX [19]. The 6-month ATTAIN
study included 391 patients randomized 2:1 to receive abata-
cept or placebo on a background of disease-modifying anti-
rheumatic drugs (DMARDs) [21]. Both studies were approved
by ethical review boards, and written informed consent was
obtained from the patients.
Outcomes assessment
In addition to the primary efficacy endpoints (ACR responses,
HAQ-DI and radiographic progression for AIM; ACR responses
and HAQ-DI for ATTAIN), multiple clinical and patient-re-
ported outcomes were assessed in these studies.
Clinical outcomes
The Disease Activity Score 28 (DAS28) index combines tender
and swollen joint counts, biomarker data, and patient’s global
assessment of disease activity [22,23]. Scores of 3.2, 3.2 to
5.1, and 5.1 represent low, moderate, and high disease ac-
tivity, respectively [24–26]. A change in DAS28 score of 1.2 (i.e.
twice the measurement error) is considered to be clinically
significant [27]. Patients are considered to be in remission if
the DAS28 score is 2.6 [24].
i363V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 6 1 – 3 7 0The EULAR response criteria are based on the DAS28 and
are a function of both current disease activity and the change
in disease activity from baseline, with responses classified as
good, moderate, or none [28]. A good response is defined as an
mprovement of 1.2 and a final score of 3.2; a moderate
response is indicated by an improvement of 1.2 and a final
score of3.2, or an improvement of 0.6 to 1.2 and a final score
of 5.1; and a patient with any other combination of DAS28
improvement and final score is classified as a non-responder.
Patient-reported outcomes
Physical function was measured by the HAQ-DI, which as-
sesses patients’ ability to complete eight categories of activi-
ties of daily living [29]. Within each category, patients report
the degree of difficulty they have experienced over the past 7
days when performing these activities (none, some difficulty,
much difficulty, unable to do). An aggregate score that adjusts
for the use of aids and devices is computed on a scale of 0 to 3,
with 0 representing no disability and 3 indicating complete
disability.
Quality of life was assessed by SF-36 score, which includes
eight domain scores, including physical functioning, role limita-
tion due to physical problems, bodily pain, general health per-
ception, vitality, social functioning, role limitation due to emo-
tional problems, andmental health; all domainswere evaluated
over the previous 4 weeks [30]. The scores range from 0 to 100,
with higher scores indicating better quality of life. The scores
were normalized to a mean of 50 and standard deviation of 10
using population norms. Two summary scores were produced
from the eight domains – the physical component summary
(PCS) and the mental component summary (MCS).
Fatigue severity was measured on a 0 to 100 mm visual
analog scale, with higher scores indicating greater fatigue [31].
Sleep quality was assessed by the sleep problems index from
the Medical Outcomes Study Sleep Module (MOS-Sleep) [32].
The sleep problems index ranges from 0 to 100, with higher
scores indicating more problems with sleep and worse sleep
quality.
Activity participation
The APaQ is a validated instrument consisting of two items
that measure the degree to which patients are limited in par-
ticipating in usual daily activities due to RA over the past 30
days [18]. The ‘usual daily activities’ (as determined by the
patient), can include paid/non-paid work, household chores,
taking care of children, volunteering, and any other activities
that the patient usually does. Two questions measure two
different aspects of participation, with the first question fo-
cusing on absenteeism and the second question on presentee-
ism. The first asks ‘during the past 30 days, on about how
many days did your RA keep you from doing your usual activ-
ities?’ The response is a number of days between 0 and 30. The
second question asks ‘during the past 30 days, how oftenwere
you able to perform your usual activities completely, in spite
of your RA?’ The responses are listed as six categories, and
converted into an ‘activity completion’ score ranging from 1 to
6 (1all of the time, 2most of the time, 3a good bit of thetime, 4someof the time, 5a little of the time, and 6none of
the time). Higher scores on both items represent less activity
participation. The APaQ was administered monthly in both
the AIM and ATTAIN trials.
Statistical analysis
Three types of analyses were performed on the activity par-
ticipation data fromAIMandATTAIN. First,mean change over
time in the APaQ items were compared between treatment
groups using analysis of covariance, adjusting for baseline val-
ues. Second, a risk-adjusted predicative regressionmodel was
performed to investigate the determinants of change in activ-
ity participation. Two separate models were constructed, one
with the change from baseline in days of limited activity (first
item of the APaQ; Model 1) as the dependent variable, the
other used the change from baseline in activity completion
score (second item of the APaQ; Model 2) as the dependent
variable. Both models included change from baseline in
HAQ-DI score, SF-36 scores, patient and physician global as-
sessments, sleep problems index, pain, fatigue, tender joint
count, and swollen joint count as the independent variables.
Both regression models adjusted for confounding variables,
such as age, sex, race, duration of RA, and baseline APaQ
scores. A tolerance below 0.20 was used as an indicator of a
problem with multicollinearity for each model [33]. Third, to
examine the relationship between changes in disease status
and changes in activity participation, the changes in APaQ
were analyzed according to clinical responses as assessed by
variants of DAS28, including LowDisease Activity State (LDAS;
DAS28  3.2), DAS28 remission (DAS28  2.6), and EULAR re-
sponse categories. All calculations were based on an intent-
to-treat population, defined as all randomized patients with
post-baseline assessments who received at least one dose of
studymedication. Missing values, including those for patients
who discontinued, were imputed using the last observation
carried forward method. Drop-out rates from the AIM and
ATTAIN trials were 16.1% and 17.6%, respectively, for all
treated patients. Values were missing for the APaQ for 2.5%
and 3.9% of patients in the AIM and ATTAIN trials, respec-
tively. Analyses were performed using SAS version 9.1 (SAS
Institute Inc., Cary, NC, USA).
Results
Patient baseline characteristics
At baseline, patient characteristics in the abatacept and pla-
cebo groups were similar in both AIM and ATTAIN studies
(Table 1). Patients had moderate-to-severe RA, with mean
HAQ-DI scores ranging from 1.7 to 1.8, mean DAS28 scores of
6.4 to 6.5, and PCS and MCS scores that were considerably
below the population norm of 50.
Activity participation
Substantial limitation in activity participation was noted at
baseline. Patients reported a mean of 14 to 17 days of limited
t0–10
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proximately half a month), and amean APaQ activity comple-
tion score of 3.6 to 3.8, which indicated that, on average, pa-
tients had been able to complete their usual activities between
‘a good bit of the time’ and ‘some of the time’.
In AIM, the gains in days of activity participation between
patients on abatacept and placebo started to separate from
Month 1 after treatment, and the differences were significant
from Month 2 (P  0.005) onward (Fig. 1A). The difference be-
tween abatacept and placebo (7.97–8.95 days vs. 4.58–5.52
days) stabilized at Month 4 and was maintained through 12
months. Patients in the ATTAIN trial experienced similar im-
provements (Fig. 1B). Mean improvements for the abatacept
group (6.11–7.80 days throughout the study period) were at
least three times greater than the changes in the placebo
group (1.68–2.30 days). Changes over time in the activity com-
pletion scores followed the same pattern, with the improve-
ments seen with abatacept significantly greater than those
seen with placebo (P  0.005 from Month 3 onwards in both
studies; Figs. 1C and 1D).
To examine the actual number of days per month that pa-
tients were active (able to participate in their usual activities),
themean improvements in days of limited activity at Month 6
(in AIM and ATTAIN) and Month 12 (in AIM) were compared
(Fig. 2). In the AIM study, patients in the abatacept group re-
ported ability to participate in usual activities on only 16.3 of
30 days at baseline (Fig. 2A). After 6 months of treatment, pa-
tients were able to participate in daily activities on 24 days per
month. This represented a gain of 7.7 activity days (47.2%)
from baseline, compared with an increase of 3.9 days (23.5%)
in the placebo group (P  0.0001). At Month 12, abatacept-
Table 1 – Baseline characteristics.
AIM
(MTX-inadequate re
Abatacept 10 mg/kg*
(n433)
Age in years 51.5  12.9
Female, n (%) 337 (78)
Caucasian, n (%) 379 (88)
Duration of RA, years 8.5  7.3
HAQ-DI score (0–3) 1.7  0.7
Patient global assessment of
disease activity (0–100)
63  21
Pain (0–100) 63  21
Fatigue (0–100) 63  23
APaQ
Days of limited activity (0–30) 14.2  11
Activity completion score (1–6) 3.6  1.4
SF-36 score
Physical component 30.6  7.3
Mental component 41.8  11.4
DAS28 6.4  0.08
Note: Values in the table other than n (%) are mean ( standard devia
AIM, Abatacept in Inadequate responders toMethotrexate; APaQ, Acti
Anti-TNF INadequate responders; DAS28, Disease Activity Score 28; H
trexate; TNF, tumor necrosis factor; RA, rheumatoid arthritis; SF-36,
* Fixed-dose abatacept, 10 mg/kg according to weight range (60, 6reated patients had gained another 0.7 activity days (24.7days in usual activity participation, a 51.5% increase in active
days from baseline) when compared with 0.6 days gained in
the placebo group (21.1 days in usual activity participation, a
27.1% increase in active days from baseline; P  0.0001 for
abatacept versus placebo). In the ATTAIN study, patients had
even fewer active days at the beginning of the study (12.7 days
in the abatacept group, 14.1 days in the placebo group; Fig. 2B).
After 6 months of treatment, patients in the abatacept group
gained 7.3 days (20.0 days in usual activity participation, a
57.5% increase in active days from baseline) compared with
1.4 days gained in the placebo group (15.5 days in usual activ-
ity participation, a 9.9% increase in active days from baseline;
P  0.0002 for abatacept versus placebo).
Over the 12-month AIM study, abatacept-treated patients
gained a cumulative 100.1 days of activity participation com-
pared with the cumulative gains of 58.2 days in the placebo
group. Therefore, patients treated with abatacept nearly dou-
bled the gains in active days during the 12-month study pe-
riod. Similarly, in the 6-month ATTAIN study the patients
treated with abatacept gained a cumulative 38.1 days com-
pared with 12.8 days for patients treated with placebo.
Determinants of activity participation
From the regression analysis, the major contributors for
changes in days of limited activity (Model 1) were the PCS and
MCS of the SF-36, and patient global assessment (Table 2).
They explained over 30% of the variance in the activity data.
The PCS andMCS were the variables most highly predictive of
changes in days of limited activity (P 0.0001), with parameter
estimates of –0.32 and –0.16, respectively. Thus, a 1-unit in-
ders)
ATTAIN
(anti-TNF-inadequate responders)
Placebo
(n219)
Abatacept 10 mg/kg*
(n258)
Placebo
(n133)
50.4  12.4 53.4  12.4 52.7  11.3
179 (82) 199 (77) 106 (80)
193 (88) 248 (96) 124 (93)
8.9  7.1 12.2  8.5 11.4  8.9
1.7  0.6 1.8  0.6 1.8  0.6
63  22 69  20 69  20
63  21 71  20 69  19
66  23 73  19 71  20
14.4  12 17.1  11 15.3  11
3.6  1.4 3.8  1.4 3.7  1.4
30.7  7.5 27.5  6.9 27.8  6.3
40.8  11.2 41.3  12.4 42.9  11.9
6.4  0.11 6.5  0.9 6.5  0.8
.
articipation Questionnaire; ATTAIN, Abatacept Trial in Treatment of
DI, Health Assessment Questionnaire Disability Index; MTX, metho-
Form-36.
0, or 100 kg received 500, 750 or 1000 mg, respectively).spon
tion)
vity P
AQ-
Shortcrease (improvement) in SF-36 PCS was associated with a re-
p
p
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days of activity participation. Parameter estimates are nega-
tive for SF-36 score correlations because improvements in
these scores go in the opposite direction to improvements in
the APaQ (i.e., reductions in SF-36 represent improvements,
and reductions in APaQ scores represent worsening). For all
other outcomes assessed, parameter estimates are positive
because improvements run in the same direction (i.e., reduc-
tions in scores represent improvements). Fatigue, HAQ-DI
score, and tender joint count also contributed to changes in
days of limited activity. Key contributors to changes in activity
completion (Model 2) were the HAQ-DI, PCS, andMCS because
they explained 26% of the variance. The strongest predictor of
change in activity completion was the HAQ-DI score (param-
eter estimate 0.281; P  0.0001). Thus, a 1-unit decrease (im-
rovement) in HAQ-DI was associated with a decrease (im-
Fig. 1 – Gains in days of activity participation (A, B) and activ
trials. Adjusted mean changes from baseline were based on
covariate. *P < 0.005, †P < 0.05, ‡P = 0.005 for abatacept versurovement) of 0.28 units in the activity completion score.Other important contributors of change in activity completion
were sleep and patient global assessment. For both models,
tolerances ranged from 0.4 to 0.74, indicating that multicol-
linearity was not an issue.
Changes in activity participation according to clinical
responses
Improvements in activity participation were consistent with
changes in disease activity (Table 3). In patients achieving
LDAS (DAS28 3.2), gains in days of activity participation and
activity completion scores were about twice those for patients
who did not have LDAS at study endpoint. These differences
were equally pronounced when patients in remission (DAS28
 2.6) were compared with those who were not. Similarly,
when the results were stratified by EULAR response, patients
ompletion score (C, D) over time in the AIM and ATTAIN
lysis of covariance models using baseline values as a
cebo.ity c
ana
s plawith a good response progressed better than those with a
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ing a good EULAR response improved 11.3 days of limited ac-
tivity, compared with gains of 7.85 and 0.25 days in moderate
and non-responders, respectively. Patients who achieved a
good EULAR response also improved by 1.96 points on the
activity completion scores compared with improvements of
0.95 and 0.11 points in moderate and non-responders, re-
spectively. Similar results were observed in the ATTAIN
study (Table 3).
Discussion
In this study we examined the changes in daily activity par-
ticipation and the factors that contribute to such changes us-
ing data from the AIM and ATTAIN trials of abatacept in pa-
tients with RA. Abatacept substantively and significantly
improved patients’ ability to participate in their usual daily
activities, whether these activities were or were not work re-
lated. Improvements in activity participation were consistent
with improvements in clinical responses (LDAS, DAS28-de-
fined remission, and EULAR responses). Changes in both phys-
ical and mental aspects of quality of life were strong contrib-
Fig. 2 – (A, B) Number of days per month patients were activ
abatacept versus placebo at 6 months in ATTAIN and AIM, autors to changes in patients’ activity participation.Patients reported substantial limitations in activity partic-
ipation at baseline. Abatacept-treated patients demonstrated
meaningful improvements in the number of activity partici-
pation days byMonths 6 and 12, with gains of around 50% over
6 months in the AIM trial. There were continued gains in ac-
tivity completion scores from Months 6 to 12 for abatacept-
treated patients in the AIM trial, demonstrating that initial
improvements in productivity were maintained.
Over 6 and 12months, abatacept-treated patients reported
greater reductions in days of limited activity, and, therefore,
greater improvements in days of activity participation, com-
pared with placebo-treated patients. Significant improve-
ments were observed as early as Month 2, and the treatment
difference was maintained through 12 months in AIM and
through 6 months in ATTAIN. Considering the cumulative
number of activity days gained during the study periods, the
difference between the abatacept and placebo groups was es-
pecially prominent. Importantly, reductions in days of limited
activity for abatacept-treated patients were greater than the
minimal clinically important difference (MCID) [34] of 4 days
per month, from at least Day 57 in both AIM and ATTAIN. The
substantial and clinically meaningful improvements seen in
le to participate in their usual activities). *P < 0.0001 for
t 12 months in AIM.e (ab
nd aactivity participation, which would have an important effect
mato
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real-life impact of an effective treatment strategy over time,
when compared with a sub-optimal regimen.
It was demonstrated that patients who experienced clini-
cally meaningful improvements in clinical response (LDAS,
DAS28-defined remission, and EULAR good or moderate re-
sponse) also demonstrated greater improvements in activity
participation, as assessed by theAPaQ. Benefits to activity par-
Table 2 – Determinants of change in activity participation:
Change from baseline Parame
Model 1: Change in days of limited activity
SF-36 physical component score 0
SF-36 mental component score 0
Patient global assessment 0
Fatigue 0
HAQ-DI 1
Tender joint count 0
Intercept 0
Model 2: Change in activity completion score
HAQ-DI 0.
SF-36 physical component score 0.
SF-36 mental component score 0.
Sleep index 0.
Patient global assessment 0.
Intercept 0.
Note: Multiple regression analysis (R2  0.3193, P value F-test 0.00
limited activity [range of 0–30] and activity completion [range of 1–6]
models were adjusted for age, sex, race, duration of RA, all outcome
correlations because improvements in these scores go in the opposite
improvements, and reductions in APaQ scores represent worsening),
improvements run in the same direction (i.e., reductions in score
HAQ-DI, Health Assessment Questionnaire-Disability Index; RA, rheu
Table 3 – Improvements in activity participation according
LDAS*
Yes No
AIM n122 n482
Change in days of limited
activity (0–30)
11.10 (11.02) 6.07 (11.42) 11
Change in activity completion
score (1–6)
1.93 (1.45) 0.76 (1.73) 1
ATTAIN n37 n275
Change in days of limited
activity (0–30)
8.31 (10.38) 4.38 (11.94) 10
Change in activity completion
score (1–6)
1.41 (1.59) 0.56 (1.68) 1
Note: Data aremean (standard error); days of limited activity is express
activities. Activity completion is expressed as a score ranging from
positive values indicate improvement (reduction) in days of limited a
the statistical significance of the improvement in APaQ items and LD
was used to determine the statistical significance of the improvem
comparisons).
AIM, Abatacept in Inadequate responders toMethotrexate; APaQ, Acti
Anti-TNF INadequate responders; DAS28, Disease Activity Score 28; E
State.
* LDAS is defined as DAS28 3.2; † DAS28-defined remission is a DAS28 oticipation may be of equal, if not greater, importance to pa-
tients than improvements in clinical outcomes. Characteriz-
ing this relationship helps to interpret the real-life relevance
of clinical responses, confirming that improvements in clini-
cal outcomes are complemented by improvements in partici-
pation in daily activities. Furthermore, the magnitude of im-
provement in each APaQ item score correlated with the
magnitude of improvement in clinical response, with days of
cal and patient-reported outcomes.
stimate Partial R2 P value partial
F-test
.05) 0.2203 0.0001
.03) 0.0681 0.0001
.02) 0.0203 0.0103
.02) 0.0044 0.0216
.75) 0.0039 0.0286
.02) 0.0023 0.0694
.47) — —
.119) 0.1817 0.0181
.007) 0.0346 0.0001
.005) 0.0406 0.0001
.003) 0.0045 0.0173
.002) 0.0019 0.1186
.066) — —
oth independent (those listed in the table) and dependent (days of
ables were expressed as a change from baseline. Multiple regression
iables. Note that parameter estimates are negative for SF-36 scores
tion to improvements in the APaQ (i.e., reductions in SF-36 represent
l other outcomes assessed, parameter estimates are positive because
resent improvements). APaQ, Activity Participation Questionnaire;
id arthritis; SE, standard error; SF-36, Short Form-36.
inical response at study endpoint.
AS28-defined
remission†
EULAR response
s No Good Moderate No
6 n528 n112 n336 n106
1.01) 6.51 (11.48) 11.27 (11.30) 7.85 (10.86) 0.25 (10.95)
.47) 0.85 (1.73) 1.96 (1.48) 0.95 (1.75) 0.11 (1.46)
1 n291 n34 n129 n116
2.34) 4.45 (11.71) 8.30 (10.84) 8.06 (12.80) 1.21 (9.40)
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portion of patients with LDAS, DAS28-defined remission, and
moderate and good EULAR responses. The association be-
tween APaQ scores and these commonly used, validatedmea-
sures of clinical benefit provide evidence for the clinical rele-
vance of this measure.
Given that improved activity participation is so valuable to
patients, it is important to understand which factors contrib-
ute to changes in days of activity. Using a regression analysis
technique we assessed the impact of a variety of clinical mea-
sures on both items of the APaQ to evaluate this. Changes in
SF-36 physical and mental component measures were impor-
tant determinants of change in both items of the APaQ, even
after the adjustment of confounders and input variables.
There was some small variation in the findings between the
two models, with PCS and MCS scores being the most impor-
tant determinants of change in activity limitation, and
HAQ-DI the most important determinant of change for activ-
ity participation, although all of these outcomes influenced
both scores. Given that the two items are quite distinct con-
cepts in their own right (i.e., days of limitation relates to ab-
senteeism, while activity participation reflects presenteeism),
it is expected that slightly different factors would contribute
to the changes of these variables. In this case, both the phys-
ical andmental aspects are highly predictive of a patient being
unable to perform an activity. Once the patient is able to par-
ticipate, physical function (HAQ-DI) is more predictive of re-
strictions to conducting the activity. Taking this into consid-
eration, the small variation between these items is not
entirely surprising. The effects from the mental and physical
components were comparable in strength. These observa-
tions are consistentwith previously published findings, which
suggest that RA not only affects patients’ physical health, but
also has a tremendous effect on mental health [12]. Previous
reports on clinical trials with abatacept have demonstrated
that treatment with abatacept improved both physical and
mental health [12,13]. These findings further support the no-
tion that physicians need to look beyond traditionalmeasures
of clinical assessments, and try to understand the impact of
treatment on overall quality of life, including both physical
and mental aspects.
Participation in daily and social activities is a pivotal con-
tributor to general health and well-being; improving levels of
participation – and, thus, involvement in society – is of high
importance to patients with RA [4]. The ICF emphasizes that
functional impairment, activity limitation, and activity partic-
ipation should all be evaluated as part of a multidisciplinary
assessment of health in patients with RA. Although some of
the SF-36 domains address the levels of difficulties of activity
participation (e.g., the role physical and the role emotional
and social functioning), the APaQ provides direct assessment
on the number of active days, which is more readily interpre-
table from clinical and societal perspectives. Furthermore, be-
cause multiple factors affect activity participation, the APaQ
covers a broader scope than the particular SF-36 physical do-
mains and can be used as a measure to supplement the SF-36
to provide additional insights into the impact of an interven-
tion on a patient’s real life.The APaQ provides a real-life disease parameter that de-
scribes and quantifies the effect of treatment on days of activ-
ity participation. This simple approach allows patients and
physicians the opportunity to evaluate the direct impact that
effective treatment has on actual days of activity, allowing
increased participation in social roles, and takes the role of
patient-reported outcomes a step further towards addressing
the impact of treatment on patients’ personal lives. These
findings support the current ICF framework, which encour-
ages the health-care profession to look beyond traditional
clinical variables to other aspects of a patient’s life.
For this evaluation a global assessment of activity partici-
pation was performed, unlike previous studies that mainly
focused on one specific area of activity, namely employment
or the ability to work [35–37]. In order to provide a complete
profile of how a patient responds to treatment, measuring
work alone is obviously not sufficient. Work is not applicable
to all patients with RA, as according to prior research only 37%
to 43% of patients with RA less than 65 years old are employed
[38]. Hence, changes in work activity presented in clinical trials
would not necessarily represent the entire population, andmay
only describe a subset of patients in the study. In addition, it
should be recognized that patients who do not work may expe-
rience improvements in non-work related activities, and that
work only reflects activities during 20 to 21working days/month
and for 8 hours/day. Thus, measuring work performance alone
providesan incompletepictureof the impactof treatmenton the
majority of activities of daily living, and although employment
andproductivityare important tosocietyandshouldbeassessed
where possible, clinicians should look beyondwork productivity
and examine every day real-life activity.
Further to this, the effect of disability on individual mea-
sures of activity participationmay vary according to the value
that individuals place on affected activities [39]. Non-work ac-
tivities, such as social activities, parenting, family activities,
and volunteering can be equally important to some patients;
for example, some patients may give up activities such as
work in order to have the time, energy, or resources to perform
a parenting role. Alternatively, some patients will view em-
ployment as most important, and they may forgo other activ-
ities in order to fulfill work commitments. This further sup-
ports the concept that measuring any one specific area of
activity is insufficient, and that a broadermeasure, such as the
APaQ, would provide a more comprehensive picture of the
impact of treatment on activity.
In this study, improvements in activity participation were
also observed in patients who received placebo, although no-
tably less so than those observed in abatacept-treated pa-
tients. This may be attributed to the placebo effect often ex-
perienced in the clinical trial setting, which results from the
special care and attention patients may receive in this envi-
ronment. In addition, patients in the AIM and ATTAIN trials
were receiving background MTX or other DMARD therapy,
which may also account for some treatment effect. Impor-
tantly, significant differences between the two treatment
groups were reported in both the AIM and ATTAIN studies,
which can be attributed to treatment with abatacept.
We acknowledge there are several potential limitations of
the present study. In evaluating the contribution of clinical
[[
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may be unknown confounders or data that are not available
for incorporation, such as socioeconomic and employment
status. Nevertheless, after adjusting for age, sex, race, and
duration of RA, it was found that improvements in both items
of the APaQ were highly correlated with improvements in the
physical and mental components of SF-36. In addition, this
analysis was based on data from clinical trials, which, given
the strict enrollment criteria employed, may not be entirely
representative of patients seen in clinical practice. Therefore,
caution should be used when drawing conclusions with re-
spect to a wider RA patient population, and future research is
needed to examine usual daily activity participation in a het-
erogeneous population. Finally, while an MCID has been vali-
dated for the number of days of activity limitation, no such
threshold has been established for activity completion scores
and, therefore, it is not certain if improvements in this item
reflect clinically meaningful changes for the patient. A valida-
tion study to establish the MCID in improvement in activity
completion scores is required to confirm whether these
changes are clinically meaningful.
Conclusions
In conclusion, patientswith RA experience substantial restric-
tions in participating in daily activities, including both work
and non-work activities. Abatacept significantly improved pa-
tients’ ability to participate in usual daily activities, as as-
sessed by the APaQ, over 12 and 6 months of treatment in the
AIM and ATTAIN trials, respectively. Improvements in both
physical and mental health were found to be the most impor-
tant contributors to changes in activity participation. Changes
in activity participation were clinically meaningful and were
closely related to improvements in clinical outcomes, physical
function, and HRQoL. These data support the broader evalua-
tion of activity participation in the assessment of treatment
for RA, in alignment with the ICF model for RA assessment.
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